Thanks Senti! Also thanks for quickly finding the released abstract today.
Turtle, I understand your impatience, but just think how patient the investigators and patients have to be. Science is in control here, but let me at least share some positive news I infer from today's abstract.
MDAnderson appears on board at this point with the hypothesis that NWBO is able to select for a very specific type of DCVax-Direct dendritic cell.
Nobody likes to talk about silver bullets, but I think what they are honing in on, and making certain is used in the phase II trials, is the silver bullet for many different types of cancers. So NWBO must get dendritic cell selection exactly right -- it is a subset, imho, of what we came to know as method B dendritic cells.
Next, it appears that it may take that silver bullet no more than 8 weeks to stabilize patients if the correct dosing is used. That means a great deal in setting up the phase II trial endpoints. Finally, I am almost completely convinced that when and where necessary (another trial arm), checkpoint inhibitors will be utilized in phase II to determine how to deal with particularly stubborn cancers. I know lately we've been talking more about statistics, deadlines and potential investment return; however, we must not lose track of the fact that phase II DCVax-Direct may come very close to solving a disease human beings have faced since, well, the beginning of mankind.
News 
Market Data 
Discover 
AI
